Cedarburg Pharma Appoints Alex Tretyakov as Director of Process Development
Cedarburg Hauser Pharmaceuticals has announced the hire of Dr. Alex Tretyakov as director of process development. "In his 25 plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via scientific excellence." says Cedarburg's CEO, Tony Laughrey. "We are counting on Dr. Tretyakov to help accelerate Cedarburg Hauser's growth and are excited to have him on board."
In his new role, Dr. Tretyakov will lead the company's process and analytical development groups. Dr. Tretyakov will furthermore join CSO John Lynch in serving as the technical face of the company and contributing his insight into customer projects.
"Dr. Tretyakov has earned an excellent reputation in our industry by delivering on-time solutions with quality chemistry." says Chuck Boland, Executive VP. "These attributes are important as they ensure the success of a project and help establish Cedarburg Hauser as an industry leader."
Most recently, Dr. Tretyakov served as the Vice President of R&D at PCI Synthesis and previously held the same position at Cambridge Major Laboratories. Tretyakov holds a Ph.D in organic chemistry from the University of Oklahoma, and completed his M.S in organic chemistry and B.S. in Chemical Engineering at the Leningard Chemical Pharmaceutical Institute.
